TABLE 9.

Novel β-lactam β-lactamase inhibitor dosages for adults^a

Estimated CrCL (ml/min) or eGFR ml/min/1.73m2)b	Dosage for:
	Ceftazidime-avibactam (2-h infusion)	Ceftolozane-tazobactam (1-h infusion)c	Meropenem-vaborbactam (3-h infusion)	Imipenem-relebactam-cilastatin (0.5-h infusion)
≥90	2.5 g (2 g-0.5 g) × 3/day	cUTI/cIAI: 1.5 g (1 g-0.5 g) × 3/day HABP/VABP: 3 g × 3/day	4 g (2 g-2 g) × 3/day	1.25 g (500 mg-200 mg-500 mg) × 4/day
50–89	2.5 g × 3/day	cUTI/cIAI: 1.5 g × 3 days HABP/VABP: 3 g × 3/day	4 g (2 g-2 g) × 3/day	1 g (400 mg-400 mg-200 mg) × 4/day for CrCL ≥60 ml/min
30–49	1.25 g (1 g-0.25 g) × 3/day	cUTI/cIAI: 750 mg (500 mg-250 mg) × 3/day HABP/VABP: 1.5 g × 3/day	2 g (1 g-1 g) × 3/day	0.75 g (300 mg-300 mg-150 mg) × 4/day for CrCL <60 ml/min
15–29	0.94 g (0.75 g-0.19 g) × 2/day	cUTI/cIAI: 375 mg (250 mg-125 mg) × 3/day HABP/VABP: 750 mg × 3/day	2 g (1 g-g) × 2/day	0.5 g (200 mg-200 mg-100 mg) × 4/day
End stage renal disease on hemodialysis for CrCL of:		cUTI/cIAI: loading dose of 750 mg, followed by 150 mg (100 mg-50 mg) × 3/day HABP/VABP: loading dose of 2.25 g (1.5 g-0.75 g), followed by 450 mg (300 mg-150 mg) × 3/dayd	1 g (0.5 g-0.5 g) × 2/dayd	0.5 g (200 mg-200 mg-100 mg) × 4/dayd
6–15	0.94 g (0.75 g-0.19 g) × 1/day
≤5	0.94 g (0.75 g-0.19 g) every 48 hd

^aAdopted from relevant FDA labels, see these labels for pediatric dosages (76, 138, 187, 222).

^bCreatinine clearance (CrCL) calculated for ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam-cilastatin according to Cockroft-Gault formula, and estimated glomerular filtration rate (eGFR) calculated for meropenem-vaborbactam according to the Modification of Diet in Renal Disease (MDRD) formula.

^ccUTI/cIAI, complicated urinary tract infection and complicated intra-abdominal infection; HABP/VABP, hospital-acquired and ventilator-associated bacterial pneumonia.

^dAdministered after hemodialysis on hemodialysis days.